产品说明

一般描述

A cell-permeable urea-substituted thioisobutyric acid (ureido-TiBA) compound that acts as a potent and selective PPARα agonist (PPARα, γ and δ - EC₅₀ = 6 nM, 1.1 µM and 6.2 µM for human; 1 nM, 1.3 µM and 2.9 µM for murine, respectively). Also displays in vivo lipid-lowering activity in rats.
A cell-permeable, urea-substituted, thioisobutyric acid (ureido-TiBA) compound that acts as a potent and selective peroxisome proliferator-activated receptor α (PPARα) agonist (EC₅₀ = 6 nM for human PPARα, 1.1 µM for human PPARγ, and 6.2 µM human PPARδ; 1 nM for murine PPARα, 1.3 µM for murine PPARγ, and 2.9 µM murine PPARδ). Also shown to lower lipid levels in rats.

包装

5 mg in Plastic ampoule
Packaged under inert gas

生化/生理作用

Cell permeable: yes
Primary Target
PPARα
Product does not compete with ATP.
Reversible: no
EC50 = 6 nM, 1.1 µM and 6.2 µM for human PPARα, γ and δ, respectively; EC50 = 1 nM, 1.3 µM and 2.9 µM for murine PPARα, γ and δ, respectively

警告

Toxicity: Irritant (B)

其他说明

Muoio, D.M., et al. 2002. J. Biol. Chem.277, 26089.
Brown, P.J., et al. 2001. Bioorg. Med. Chem. Lett.11, 1225.
Oliver, W.R. Jr., et al. 2001. Proc. Natl. Acad. Sci. USA98, 5306.
Poirier, H., et al. 2001. Biochem. J.355, 481.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

基本信息

产品性质

安全信息

产品说明

应用

GW7647已被用作过氧化物酶体增殖物激活受体α (PPAR α)配体：

• 脱脂培养基，用于治疗原代人肝细胞
• 测试对心肌细胞糖酵解功能的影响
• 测试对幼鼠心脏的影响
• 在乳腺癌MDA-MB-231细胞中激活PPAR

包装

5, 25 mg in glass bottle

生化/生理作用

GW7647可降低血清甘油三酯水平，提高β-氧化相关基因的肝脏表达。GW7647与二甲双胍联合应用可提高肝脏脂肪变性或损伤情况下血清中天冬氨酸转氨酶(AST)和丙氨酸转氨酶(ALT)的水平。
强效人PPARα激动剂。用于研究人细胞中PPARα受体的生物学。

特点和优势

该化合物在受体分类和信号转导手册中核受体(PPAR)页面中进行了详细介绍。如需浏览其他手册页，请点击此处。

法律信息

根据Glaxo­Smith­Kline协议，仅为研究目的出售

基本信息

产品性质

安全信息